Cargando…

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report

We report the case of a 32-year-old man with a caecal adenocarcinoma with major lymph node extension and peritoneal carcinomatosis, presenting a BRAF-K601E mutation. A triplet (5FU plus oxaliplatin plus irinotecan) combination with bevacizumab achieved tumor control but the disease progressed immedi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moisset, Laure, Raimbourg, Judith, Hiret, Sandrine, Dauve, Jonathan, Boisdron-Celle, Michèle, Senellart, Hélène, Raoul, Jean-Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587192/ https://www.ncbi.nlm.nih.gov/pubmed/31244646 http://dx.doi.org/10.1159/000500857

Ejemplares similares

Transient Vision Loss − A Rare Oxaliplatin-Induced Ophthalmologic Side Effect: A Report of Two Cases
por: Ah-Thiane, Loic, et al.
Publicado: (2021)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

BRAF(V600E) Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
por: Gourdin, Guillaume, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010)

Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
por: Kanat, Ozkan, et al.
Publicado: (2020)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
por: Guerrero, Rodrigo Motta, et al.
Publicado: (2022)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Intratumor morphologic and transcriptomic heterogeneity in (V600E)BRAF-mutated metastatic colorectal adenocarcinomas
por: Angerilli, V., et al.
Publicado: (2021)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2022)

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma
por: Rusu, Stefan, et al.
Publicado: (2021)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
por: Wang, Zhan, et al.
Publicado: (2019)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2019)

The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
por: Ye, Liu-Fang, et al.
Publicado: (2021)

Nursing care and management of adverse events for patients with BRAF(V600E)-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review
por: Fowler, Matthew, et al.
Publicado: (2023)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Insight on BRAF(V600E) mutated colorectal cancer immune microenvironment
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Impact of encorafenib on survival of patients with BRAF(V600E)-mutant metastatic colorectal cancer in a real-world setting
por: Zurloh, M., et al.
Publicado: (2023)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Real-world first-line treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer: the CAPSTAN CRC study
por: Martinelli, E., et al.
Publicado: (2022)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

Intra- and Inter-Tumor Heterogeneity of BRAF(V600E)Mutations in Primary and Metastatic Melanoma
por: Yancovitz, Molly, et al.
Publicado: (2012)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Metastatic BRAF V600E-Mutated Adenocarcinoma of the Lung Presenting as Extreme Neutrophilia and Eosinophilia
por: Muhammad, Azharuddin, et al.
Publicado: (2021)

Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()
por: Babačić, Haris, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rboc0bjq6lgjter3erhv1517ih